Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (159)	1/18/1999 12:32:00 PM
From: Abuckatatime	Read Replies (1) \| Respond to of 613

TD, That article described the correction of hemophilia B in the models following intrahepatic (portal vein) infusion of the viral vector with no mention of the use of an ATRX drug delivery system. Were you presuming an ATRX connection? Perhaps I missed something. I see the authors with ties to Cell Genesys, Univ Of WA, Stanford U, and U of NC.

To: Arthur Radley who wrote (159)	1/18/1999 12:55:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 613

A search for AAV here on SI should turn up... Ariad, ARIA--EPO, ARGENT Vical--I do not own this one Cell Genesis--traded it, not in it now Targeted Genetics, TGEN--Gene therapy CF, expect a quick pop after Seattle Times coverage in Sunday paper Avigen--AVGN--broad patents, maybe too broad too late? I traded this one and sold way too early, that really bugs me:-( If anybody has a more complete list of those small biotech companies which are into aav vector or lentivirus etc I'd sure appreciate it, I think it was Avigen which was working on hemophillia, but I'm not sure.